Immunome Inc. IMNM
Institutional shares held
32.1 Million
46.1K
calls
32.5K
puts
Total value of holdings
$444M
$637K
calls
$449K
puts
Market Cap
$168M
12,127,400
Shares Out.
Institutional ownership
264.55%
# of Institutions
106
We take great care to ensure that the data presented and summarized in this overview for Immunome Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding IMNM
View all-
Redmile Group, LLC San Francisco, CA4.89MShares$67.6 Million4.76% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA3.88MShares$53.7 Million2.73% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.25MShares$31.1 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.02MShares$27.9 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct1.64MShares$22.7 Million0.1% of portfolio
-
Janus Henderson Group PLC London, X01.54MShares$21.3 Million0.02% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD1.52MShares$21 Million0.02% of portfolio
-
Woodline Partners LP San Francisco, CA1.32MShares$18.2 Million0.31% of portfolio
-
Avidity Partners Management LP Dallas, TX874KShares$12.1 Million0.83% of portfolio
-
Black Rock Inc. New York, NY829KShares$11.5 Million0.0% of portfolio
Latest Institutional Activity in IMNM
Top Purchases
Top Sells
About IMNM
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
Insider Transactions at IMNM
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 02
2023
|
Clay B Siegall President and CEO |
BUY
Open market or private purchase
|
Direct |
169,204
+34.61%
|
$846,020
$5.91 P/Share
|
|
Oct 02
2023
|
Bruce Turner Chief Strategy Officer |
BUY
Open market or private purchase
|
Direct |
42,300
+50.0%
|
$211,500
$5.91 P/Share
|
|
Oct 02
2023
|
Franklyn G Prendergast Director |
BUY
Grant, award, or other acquisition
|
Direct |
60,840
+50.0%
|
-
|
|
Oct 02
2023
|
Michael Rapp Director |
BUY
Grant, award, or other acquisition
|
Direct |
253,806
+19.16%
|
$1,269,030
$5.91 P/Share
|
|
Jan 15
2023
|
Philip Wagenheim Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,750
+2.11%
|
$35,000
$4.0 P/Share
|
|
Jan 15
2023
|
Michael Rapp Director |
BUY
Grant, award, or other acquisition
|
Direct |
17,500
+2.1%
|
$70,000
$4.0 P/Share
|
|
Jan 15
2023
|
Michael Lefenfeld Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,875
+25.4%
|
$55,500
$4.0 P/Share
|
|
Jan 15
2023
|
John L Lamattina Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,125
+18.43%
|
$60,500
$4.0 P/Share
|
|
Sep 13
2021
|
Michael Rapp Director |
BUY
Open market or private purchase
|
Indirect |
25,962
+11.06%
|
$493,278
$19.96 P/Share
|
|
Sep 10
2021
|
Michael Rapp Director |
BUY
Open market or private purchase
|
Indirect |
15,500
+7.82%
|
$263,500
$17.85 P/Share
|
|
Sep 09
2021
|
Michael Rapp Director |
BUY
Open market or private purchase
|
Indirect |
30,450
+8.54%
|
$517,650
$17.95 P/Share
|
|
Aug 18
2021
|
Richard A Baron Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,343
+50.0%
|
$25,773
$11.38 P/Share
|
|
May 26
2021
|
Michael Rapp Director |
BUY
Open market or private purchase
|
Indirect |
2,300
+1.65%
|
$41,400
$18.94 P/Share
|
|
May 26
2021
|
Michael Lefenfeld Director |
BUY
Open market or private purchase
|
Direct |
1,335
+4.73%
|
$25,365
$19.03 P/Share
|
|
May 25
2021
|
Purnanand D Sarma President and CEO |
BUY
Open market or private purchase
|
Direct |
10,500
+50.0%
|
$189,000
$18.41 P/Share
|
|
May 25
2021
|
Michael Rapp Director |
BUY
Open market or private purchase
|
Indirect |
19,303
+12.55%
|
$347,454
$18.32 P/Share
|
|
May 25
2021
|
Michael Lefenfeld Director |
BUY
Open market or private purchase
|
Direct |
2,715
+9.61%
|
$48,870
$18.44 P/Share
|
|
May 24
2021
|
John L Lamattina Director |
BUY
Open market or private purchase
|
Direct |
5,440
+4.84%
|
$97,920
$18.51 P/Share
|
|
May 24
2021
|
Philip Wagenheim Director |
BUY
Open market or private purchase
|
Direct |
13,500
+3.29%
|
$243,000
$18.35 P/Share
|
|
May 24
2021
|
Michael Rapp Director |
BUY
Open market or private purchase
|
Indirect |
31,895
+21.68%
|
$574,110
$18.38 P/Share
|
Last 12 Months Summary
Buy / Acquisition
526K
Shares
From
4
Insiders
| Grant, award, or other acquisition | 315K shares |
|---|---|
| Open market or private purchase | 212K shares |
Sell / Disposition
0
Shares
From
0
Insiders